glimepiride has been researched along with Cardiovascular Stroke in 11 studies
glimepiride: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, on the development of myocardial infarction has been compared." | 7.70 | Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats. ( Baczkó, I; El-Reyani, NE; Leprán, I; Papp, JG, 2000) |
| "Using nationwide administrative Danish registries, we followed all individuals without prior stroke or myocardial infarction who initiated metformin and an IS from 1997 through 2009." | 3.81 | Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study. ( Andersson, C; Fosbøl, EL; Gislason, G; Køber, L; Mogensen, UM; Scheller, NM; Schramm, TK; Torp-Pedersen, C; Vaag, A, 2015) |
| "The effect of glibenclamide and glimepiride, two orally active antidiabetic sulphonylurea derivatives, on the development of myocardial infarction has been compared." | 3.70 | Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats. ( Baczkó, I; El-Reyani, NE; Leprán, I; Papp, JG, 2000) |
| " We compared the effects of three SU medications and initial SU doses on adverse glycemic and cardiovascular events among NH residents." | 1.91 | Comparative safety of sulfonylureas among U.S. nursing home residents. ( Berry, SD; Hayes, KN; Munshi, MN; Riester, MR; Zullo, AR, 2023) |
| "Glimepiride (10 microM) treatment for the first 10 min of reperfusion significantly reduced infarct size from 67." | 1.35 | Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit hearts. ( Miyazaki, M; Nakaya, H; Nishida, H; Nomura, M; Sato, T, 2009) |
| "Glimepiride (Glim) is a new sulfonylurea reported to affect nonpancreatic K(ATP) channels less than does Glib." | 1.31 | Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. ( Baxter, GF; Lawrence, CL; Maddock, HL; Mocanu, MM; Standen, NB; Yellon, DM, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (54.55) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Zullo, AR | 2 |
| Riester, MR | 2 |
| Hayes, KN | 2 |
| Munshi, MN | 2 |
| Berry, SD | 2 |
| Cho, EH | 1 |
| Han, K | 1 |
| Kim, B | 1 |
| Lee, DH | 1 |
| Mogensen, UM | 1 |
| Andersson, C | 1 |
| Fosbøl, EL | 1 |
| Schramm, TK | 1 |
| Vaag, A | 1 |
| Scheller, NM | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, G | 1 |
| Køber, L | 1 |
| Simpson, SH | 1 |
| Lee, J | 1 |
| Choi, S | 1 |
| Vandermeer, B | 1 |
| Abdelmoneim, AS | 1 |
| Featherstone, TR | 1 |
| Ye, Y | 1 |
| Lin, Y | 1 |
| Perez-Polo, JR | 1 |
| Birnbaum, Y | 1 |
| Argaud, L | 1 |
| Garrier, O | 1 |
| Loufouat, J | 1 |
| Gomez, L | 1 |
| Couture-Lepetit, E | 1 |
| Gateau-Roesch, O | 1 |
| Robert, D | 1 |
| Ovize, M | 1 |
| Nishida, H | 1 |
| Sato, T | 1 |
| Nomura, M | 1 |
| Miyazaki, M | 1 |
| Nakaya, H | 1 |
| Hausenloy, DJ | 1 |
| Wynne, AM | 1 |
| Mocanu, MM | 2 |
| Yellon, DM | 2 |
| Horimoto, H | 1 |
| Nakai, Y | 1 |
| Mieno, S | 1 |
| Nomura, Y | 1 |
| Nakahara, K | 1 |
| Sasaki, S | 1 |
| El-Reyani, NE | 1 |
| Baczkó, I | 1 |
| Leprán, I | 1 |
| Papp, JG | 1 |
| Maddock, HL | 1 |
| Baxter, GF | 1 |
| Lawrence, CL | 1 |
| Standen, NB | 1 |
1 review available for glimepiride and Cardiovascular Stroke
| Article | Year |
|---|---|
Mortality risk among sulfonylureas: a systematic review and network meta-analysis.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Female; Glipizide; Humans; | 2015 |
10 other studies available for glimepiride and Cardiovascular Stroke
| Article | Year |
|---|---|
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Comparative safety of sulfonylureas among U.S. nursing home residents.
Topics: Aged; Female; Glipizide; Glyburide; Humans; Hypoglycemia; Male; Medicare; Myocardial Infarction; Nur | 2023 |
Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus.
Topics: Adult; Aged; Asian People; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemic Agent | 2020 |
Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
Topics: Aged; Carbamates; Cardiovascular Diseases; Denmark; Diabetes Mellitus, Type 2; Drug Therapy, Combina | 2015 |
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Topics: Administration, Oral; Animals; Body Weight; Coronary Vessels; Data Interpretation, Statistical; Deca | 2008 |
Second-generation sulfonylureas preserve inhibition of mitochondrial permeability transition by the mitochondrial K+(ATP) opener nicorandil in experimental myocardial infarction.
Topics: Animals; Calcium; Gliclazide; Glyburide; Hemodynamics; Male; Mitochondria; Myocardial Infarction; Ni | 2009 |
Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit hearts.
Topics: Animals; In Vitro Techniques; Myocardial Infarction; Phosphatidylinositol 3-Kinases; Phosphorylation | 2009 |
Glimepiride treatment facilitates ischemic preconditioning in the diabetic heart.
Topics: Animals; Cardiotonic Agents; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Cardiomy | 2013 |
Oral hypoglycemic sulfonylurea glimepiride preserves the myoprotective effects of ischemic preconditioning.
Topics: Action Potentials; Animals; Coronary Circulation; Heart; Hypoglycemic Agents; In Vitro Techniques; I | 2002 |
Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats.
Topics: Animals; Coronary Vessels; Glyburide; Heart Ventricles; Hypoglycemic Agents; Image Processing, Compu | 2000 |
Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide.
Topics: Animals; Diazoxide; Glyburide; Guanosine Triphosphate; Heart; Heart Ventricles; Hemodynamics; Hypogl | 2001 |